Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD Forest Laboratories, Inc. and Almirall, S.A buy dapoxetine . announced they have recently submitted a New Drug Application to the U.S. Food and Medication Administration for aclidinium bromide, a long-performing inhaled antimuscarinic agent developed for the treatment of COPD. The submission contains efficacy data from a large Phase III double-blind placebo-controlled program where patients received aclidinium bromide 400 mcg or 200 mcg twice daily or placebo.
Commenting on the agreement renewal, Ian Bowles, Allocate Software’s CEO said: We are delighted that NHS Experts, after consideration and complete discussions have committed to the long term usage of StaffBank as the software application of choice to support the services they offer to NHS Trusts. This contract demonstrates Allocate Software’s long term commitment to the NHS. Our objective is to continue dealing with the NHS to create and build solutions that can be quickly deployed and so are user friendly, whilst simultaneously delivering significant ROI, assisting to improve efficiency, keep your charges down and achieve optimum degrees of patient care.